{"id":"W4213072175","doi":"10.1200/jco.2022.40.6_suppl.487","title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer","keywords":"Medicine; Avelumab; Metastatic Urothelial Carcinoma; Internal medicine; Randomization; Clinical endpoint; Urology; Randomized controlled trial; Progression-free survival; Oncology; Carboplatin; Gemcitabine; Chemotherapy; Surgery; Bladder cancer; Urothelial carcinoma; Cisplatin; Nivolumab; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002598129,0.000573015,0.001189916,0.0002122091,0.0003147217,0.0009935721,0.0005865979,0.0008822663,0.003548072],"category_scores_gemma":[0.00141989,0.0003081051,0.001425214,0.0003633139,0.0005141998,0.0007477351,0.0003682779,0.002085331,0.0006875353],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007043805,"about_ca_system_score_gemma":0.0006903977,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005702624,"about_ca_topic_score_gemma":0.001968923,"domain_scores_codex":[0.9993585,0.0003903038,0.00003350436,0.00008006288,0.00005439265,0.00008328438],"domain_scores_gemma":[0.9989799,0.0002249544,0.0003409556,0.0001003498,0.00004538165,0.0003084713],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8561772,0.01097356,0.01498059,0.001639792,0.004027507,0.0001345229,0.0001746751,0.001370642,0.008596231,0.0002107337,0.007510103,0.09420452],"study_design_scores_gemma":[0.7045259,0.2143441,0.06256109,0.0002989128,0.004738727,0.0005436263,0.00009701034,0.001483949,0.002855046,0.0004863927,0.008006304,0.00005889537],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9808756,0.01187853,0.0004913323,0.0008168562,0.0001565639,0.0008121586,0.002776818,0.00008332993,0.002108849],"genre_scores_gemma":[0.9872531,0.003668368,0.0007783611,0.0008573735,0.0001569953,0.001058256,0.004221565,0.00002729765,0.001978556],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003548072,"threshold_uncertainty_score":0.01374036,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1320019420863733,"score_gpt":0.4295972215872962,"score_spread":0.297595279500923,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}